Is lamotrigine appropriate for treating major depressive disorder?

Lamotrigine for Major Depressive Disorder

Lamotrigine is NOT recommended as a standard treatment for unipolar major depressive disorder, as it is not included in evidence-based guidelines for MDD and lacks robust efficacy data in this population. The American College of Physicians guidelines for treating MDD recommend selecting between cognitive behavioral therapy or second-generation antidepressants (SSRIs, SNRIs) as first-line treatments, with no mention of lamotrigine 1.

Primary Treatment Recommendations for MDD

For unipolar major depressive disorder, clinicians should select second-generation antidepressants based on adverse effect profiles, cost, and patient preferences 1. The evidence-based options include:

• Selective serotonin reuptake inhibitors (SSRIs): fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine 1
• Serotonin-norepinephrine reuptake inhibitors (SNRIs): venlafaxine, duloxetine 1
• Other second-generation antidepressants: bupropion, mirtazapine 1
• Cognitive behavioral therapy as an alternative or adjunct to pharmacotherapy 1

Evidence Against Lamotrigine in Unipolar Depression

The research evidence for lamotrigine in unipolar depression is weak and contradictory:

• Meta-analyses including unpublished studies show lamotrigine is NOT superior to placebo in monotherapy or as adjunct treatment for unipolar depressive episodes 2
• A 2013 review concluded that while lamotrigine has the best evidence for bipolar disorder maintenance, data in unipolar depression warrant more research before recommendation 3
• Individual studies show mixed results, with some suggesting modest effects on specific depressive symptoms but no overall superiority 4, 5, 6

Critical Caveat on Study Quality

The positive studies cited for unipolar depression are small, open-label trials or retrospective reviews with significant methodological limitations 4, 5, 6. When rigorous double-blind methodology and unpublished data are included, the benefit disappears 2.

Where Lamotrigine IS Appropriate: Bipolar Depression

Lamotrigine has FDA approval and guideline support specifically for bipolar disorder, not unipolar MDD:

• FDA-approved for maintenance therapy in bipolar disorder (adults) 1
• Effective for acute bipolar depression in monotherapy versus placebo (SMD: 0.155; CI: 0.005-0.305) 2
• Reduces risk of depressive episode emergence in bipolar prophylaxis (RR: 0.78; CI: 0.63,0.98) 2
• The combination of olanzapine and fluoxetine is FDA-approved for bipolar depression in adults 1

Treatment Algorithm for MDD

When treating major depressive disorder:

1. First-line: Initiate second-generation antidepressant (SSRI/SNRI) or CBT 1
2. Monitor response: Assess within 1-2 weeks, then regularly 1
3. If inadequate response at 6-8 weeks: Modify treatment by switching antidepressants, increasing dose, or adding augmentation 1
4. Duration: Continue 4-9 months after response for first episode; longer for recurrent episodes 1

Lamotrigine is not part of this evidence-based algorithm for unipolar MDD 1.

Safety Considerations

If lamotrigine were to be considered off-label despite lack of evidence:

• Risk of serious rash including Stevens-Johnson syndrome, requiring slow dose titration 7
• Neutropenia reported in clinical trials 4
• No established therapeutic dose for unipolar depression 6
• No pharmacokinetic interaction with SSRIs like paroxetine 4

Bottom Line

Use evidence-based treatments for MDD: second-generation antidepressants or CBT 1. Lamotrigine should be reserved for its FDA-approved indication in bipolar disorder maintenance 1, 2. The 2023 CANMAT guidelines for depression management do not recommend lamotrigine for unipolar MDD 8, and the most recent systematic review (2025) confirms lack of efficacy in unipolar disorders 2.